Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Novo Nordisk A/S NVO
$170.48
+$1.5 (0.88%)
На 18:00, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
374878410950.00000000
-
week52high
172.97
-
week52low
95.02
-
Revenue
176954000000
-
P/E TTM
181
-
Beta
0.30992300
-
EPS
3.62000000
-
Last Dividend
1.76000000
-
Next Earnings Date
05 мая 2023 г. в 04:00
Описание компании
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| UBS | Sell | Neutral | 28 июн 2022 г. |
| JP Morgan | Overweight | Neutral | 07 июн 2022 г. |
| Guggenheim | Buy | Neutral | 31 мая 2022 г. |
| Deutsche Bank | Buy | Hold | 16 мар 2022 г. |
| Liberum | Sell | Hold | 25 янв 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate
Market Watch
11 мая 2023 г. в 14:46
A bipartisan effort to rein in prescription drug prices advanced Thursday as a key U.S. Senate committee approved a bill aimed at reforming pharmacy benefit managers.
Novo Nordisk (NVO) is an Incredible Growth Stock: 3 Reasons Why
Zacks Investment Research
08 мая 2023 г. в 14:26
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Why Novo Nordisk Stock Is Marching Higher Today
The Motley Fool
08 мая 2023 г. в 12:54
Last week, Novo's shares dipped on the news that it can't keep up with demand for its weight-loss medication Wegovy. Investors initially reacted poorly to this revelation due to a potential near-term competitive threat.
Buy These 4 Low-Beta Stocks to Endure Market Volatility
Zacks Investment Research
05 мая 2023 г. в 09:09
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.
Why Novo Nordisk Stock Is Slumping Today
The Motley Fool
04 мая 2023 г. в 12:33
Danish pharma giant Novo Nordisk reported strong 2023 Q1 results today. Even so, the company announced plans to start rationing lower-strength starter doses of its popular weight-loss drug.